Claims
- 1. A vector comprising at least two oncogenes and a pair of genetic elements flanking the oncogenes, wherein the genetic elements comprise recombination sites.
- 2. The vector of claim 1, wherein the vector comprises two or three oncogenes.
- 3. The vector of claim 2 wherein the vector is a retroviral vector.
- 4. The retroviral vector of claim 3, wherein the oncogenes are Ras and SV40 T-Ag.
- 5. The vector of claim 1, further comprising an exogenous gene which is inserted into the vector.
- 6. The vector of claim 1, further comprising one or more inducible promoters, wherein the expression of each oncogene is under the transcriptional control of an inducible promoter.
- 7. The vector of claim 6, wherein the vector is a recombinant virus encoding two or three oncogenes and at least one inducible promoter.
- 8. A vector comprising a first gene that is an oncogene and a second gene that encodes an effector of ras, said vector further comprising a pair of genetic elements flanking the first and second genes, wherein the genetic elements comprise recombination sites.
- 9. A cell transfected by a vector, wherein the vector comprises at least two oncogenes and a pair of genetic elements flanking the oncogenes, and wherein the genetic elements comprise recombination sites.
- 10. Progeny of the cell of claim 9.
- 11. The cell of claim 9, wherein the cell is a human cell.
- 12. A mammalian cell comprising recombination sites not naturally found in the cell, wherein at least one oncogene lies between said recombination sites.
- 13. A non-naturally occurring cell produced by transforming a cell with one or more oncogenes, allowing the cell to divide at least once and then removing the oncogenes from the cell by expressing a recombinase in the cell.
- 14. The cell of claim 13 wherein expression of the recombinase is under the control of an inducible promoter.
- 15. The cell of claim 13 wherein the recombinase is Cre recombinase or FLP recombinase.
- 16. The cell of claim 13 wherein the inducible promoter is the lac operator inducible promoter.
- 17. A method for producing a non-naturally occurring cell comprising transforming a cell with a retroviral vector comprising at least one oncogene flanked by recombination sites, allowing the transformed cell to divide at least once, and introducing recombinase into the cell, whereupon the oncogenes are excised.
- 18. The method of claim 17 wherein (i) the recombination sites are from bacteriophage PI and the recombinase is Cre recombinase, or (ii) the recombination sites are from FLP target sites and the recombinase is FLP.
- 19. The method of claim 18 wherein the recombinase is encoded by a gene under the transcriptional control of an inducible promoter and the step of introducing the recombinase into the cell comprises inducing transcription of the gene.
- 20. The method of claim 19 wherein the inducible promoter is the lac operator inducible promoter.
- 21. The method of claim 17 wherein the cell is from pancreas.
- 22. A cell produced by the method of claim 21.
- 23. A cell of claim 22, wherein the cell produces insulin.
- 24. A pancreatic cell comprising two or more exogenous oncogenes flanked by recombination sites not naturally found in the cell.
- 25. The pancreatic cell of claim 24, comprising two or three oncogenes.
- 26. A cell of claim 25, wherein said cell is of human origin and wherein said cell comprises ras and SV40 T-Ag.
- 27. Progeny of the cell of claim 24.
- 28. A method for human cell transplantation therapy comprising transplanting a genetically modified human cell into a human host, the genetically modified human cell having been produced by the method comprising the steps of:
(a) transfecting a human cell with a vector comprising at least two oncogenes which are capable of expression in the human cell to induce its multiplication; and (b) transplanting the cell into the human host.
- 29. The method of claim 28, further comprising the step of suppressing or removing said oncogenes before transplanting the cell into the human host.
- 30. The method of claim 29, wherein the human cell is a precursor cell, and the method further comprises: suppressing expression of or removing the oncogenes to allow differentiation of the precursor cell into a mature cell before transplanting it into the human host.
Parent Case Info
[0001] This is a continuation-in-part patent application of U.S. patent application Ser. No. 08/509,121 filed on Jul. 31, 1995 which was a continuation-in-part patent application of U.S. patent application Ser. No. 08/386,897 filed on Feb. 10, 1995, both of which are incorporated by reference in their entirety.
Government Interests
[0002] This invention was made with Government support under Grant No. 1R01DK50171-01, awarded by the National Institutes of Health. The Government has certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09636389 |
Aug 2000 |
US |
Child |
10402194 |
Mar 2003 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08883640 |
Jun 1997 |
US |
Child |
09636389 |
Aug 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08509121 |
Jul 1995 |
US |
Child |
08883640 |
Jun 1997 |
US |
Parent |
08386897 |
Feb 1995 |
US |
Child |
08509121 |
Jul 1995 |
US |